机构地区:[1]Clinical Laboratory Medicine Department,The Second Affiliated Hospital of Guangzhou Medical University,Guangzhou,510260,China [2]State Key Laboratories of Respiratory Diseases,Guangdong-Hong Kong-Macao Joint Laboratory of Infectious Respiratory Disease,Guangzhou Institutes of Biomedicine and Health,Chinese Academy of Sciences,Guangzhou,510535,China [3]Clinical Laboratory Medicine Department,Dongguan Ninth People's Hospital,Dongguan,523016,China [4]State Key Laboratory of Respiratory Disease,Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,510120,China [5]Clinical Laboratory Medicine Department,Maoming People's Hospital,Maoming,525000,China [6]Laboratory of Pathology,Department of Pathobiology,University of Poonch Rawalakot Azad Kashmir Pakistan 12350,Pakistan [7]Hospital Infection-Control Department,The Second Affiliated Hospital of Guangzhou Medical University,Guangzhou,510260,China [8]Medical Examination Department,The Second Affiliated Hospital of Guangzhou Medical University,Guangzhou,510260,China [9]Department of Clinical Laboratory Medicine,The Third Affiliated Hospital of Guangzhou Medical University,Guangzhou,510140,China [10]Kidney Transplant Department,The Second Affiliated Hospital of Guangzhou Medical University,Guangzhou,510260,China [11]Department of Organ Transplantation,The Third Affiliated Hospital of Sun Yat-sen University,510630,China [12]Guangzhou Key Laboratory for Clinical Rapid Diagnosis and Early Warning of Infectious Diseases,KingMed School of Laboratory Medicine,Guangzhou Medical University,Guangzhou,511436,China
出 处:《Virologica Sinica》2023年第2期233-243,共11页中国病毒学(英文版)
基 金:Guangzhou Health Science and Technology Project(20201A011078);Guangzhou Science and Technology Project(202102010094);Guangdong Basic and Applied Basic Research Foundation(2021A1515012550);Clinical research project of Guangzhou Medical University Second Affiliated Hospital(2021-LCYJ-05);Guangdong Medical Research Fund(A2022255);Key Clinical Specialty of Guangzhou Medical University(0F03031);Guangzhou Laboratory(EKPG21-30-3);Guangzhou key discipline of urology.The funding sources had no role in the study design,data collection,analysis,interpretation,or writing of the report.
摘 要:Homologous booster,heterologous booster,and Omicron variants breakthrough infection(OBI)could improve the humoral immunity against Omicron variants.Questions concerning about memory B cells(MBCs)and T cells immunity against Omicron variants,features of long-term immunity,after booster and OBI,needs to be explored.Here,comparative analysis demonstrate antibody and T cell immunity against ancestral strain,Delta and Omicron variants in Omicron breakthrough infected patients(OBIPs)are comparable to that in Ad5-nCoV boosted healthy volunteers(HVs),higher than that in inactivated vaccine(InV)boosted HVs.However,memory B cells(MBCs)immunity against Omicron variants was highest in OBIPs,followed by Ad5-nCoV boosted and InV boosted HVs.OBIPs and Ad5-nCoV boosted HVs have higher classical MBCs and activated MBCs,and lower naïve MBCs and atypical MBCs relative to both vaccine boosted HVs.Collectively,these data indicate Omicron breakthrough infection elicit higher MBCs and T cells against SARS-CoV-2 especially Omicron variants relative to homologous InV booster and heterologous Ad5-nCoV booster.
关 键 词:Inactivated vaccine booster Ad5-nCoV booster Omicron variants breakthrough infection Memory immunity Binding antibody
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...